



Acinetobacter infections in critical care units – A study on its clinico epidemiological pattern and antibiotic sensitivity profile from a rural teaching hospital in West Bengal, India.

Dr Anirban Bhaduri¹, Dr Paulami Palchowdhury², Dr Somnath Ghosh³, Dr Sayani Bose^{4*}

^{1*}Associate Professor and HOD, Department of Microbiology, Tamralipto Government Medical College and Hospital, Tamluk, Purba Medinipur, West Bengal, India

²Senior Resident, Department of Microbiology, Sarat Chandra Chattopadhyay Government Medical College and Hospital, Uluberia, Howrah, West Bengal.

³Assistant Professor, Department of Pathology, Malda Medical College and Hospital, Malda, West Bengal, India

***Corresponding author – Dr Sayani Bose**

Senior Resident, Department of Microbiology, Tamralipto Government Medical College and Hospital, Tamluk, Purba Medinipur, West Bengal, India

ABSTRACT

BACKGROUND- *Acinetobacter spp* has emerged as an important cause of nosocomial infection among immunocompromised patients and those with prolonged hospital stay, particularly in intensive care units (ICUs). These infections are often difficult to treat due to the widespread resistance of the bacteria to major groups of antibiotics. Therefore, antibiotic selection for empirical therapy is challenging and must be relied upon recent institutional-level susceptibility data.

AIMS- To determine the clinico-epidemiological profile of *Acinetobacter spp* isolated from different ICU patients and to identify their antibiotic sensitivity pattern in a rural tertiary care hospital.

MATERIALS AND METHODS- The study was conducted from August 2023 to July 2024 at the Department of Microbiology of Tamralipto Government Medical College and Hospital, Tamluk, West Bengal with 1911 samples received from patients admitted in the intensive care units of various department of our hospital.

The aseptically collected specimens were inoculated on MacConkey agar & Blood agar and incubated aerobically at 37°C for 24-48 hrs. Presumptive identification was done on the basis of colony characteristics and Gram staining, followed by confirmation with standard biochemical tests.

Antibiotic sensitivity testing was performed by KirbyBauer disk-diffusion method on Muller Hinton Agar according to CLSI (Clinical Laboratory Standard Institute) guidelines 2023.

RESULTS- Out of total 1911 clinical samples 1160 turned out to be culture positive and out of those culture positives, *Acinetobacter spp* was detected from 54 samples (4.66%). Maximum number were detected from pus samples (35.19%) followed by blood (22.22%), urine (18.52%), respiratory samples and other body fluids. Elderly age group (>60 years) was the most affected by *Acinetobacter spp* infection. >80% resistance was observed towards several classes of antibiotics such as Aminoglycosides, Cephalosporins, Fluoroquinolones, Tetracyclines while maximum sensitivity was seen towards Colistin.

CONCLUSION- The MDR nature of *Acinetobacter spp* poses a severe threat to immunocompromised patients and ICU inhabitants which highlights the importance of surveillance at health-care setups to identify colonizers and plan effective infection control strategies, combined with antibiotic stewardship program for developing new treatment options.

KEY WORDS – *Acinetobacter spp*, MDR, Nosocomial infections.

INTRODUCTION-

Acinetobacter spp. is a ubiquitous saprophytic gram negative coccobacilli which has emerged as a serious and important cause of nosocomial infections like septicemia, pneumonia, wound sepsis, endocarditis, meningitis and urinary tract infection (UTI) in hospitals worldwide.^{1,2} *Acinetobacter* infections are highly observed in immunocompromised patients and those with prolonged hospital stay, particularly among patients in intensive care units (ICUs), resulting in high morbidity and mortality.^{3,4}

These infections are often difficult to treat due to the widespread resistance of the bacteria to major groups of antibiotics.² This is because *Acinetobacter* is known for its intrinsic resistance to antibiotics as well as its ability to acquire resistance genes as mobile genetic elements such as plasmids, transposons, integrons cassettes and insertion sequences.⁵⁻⁷

Due to the above reasons, antibiotic selection for empirical therapy is challenging and must be relied upon recent institutional-level susceptibility data.⁸ Therefore, the current study was undertaken to evaluate the



clinico-epidemiological profile of *Acinetobacter* spp. infections and find the recent trend of drug resistance amongst these bacteria in a tertiary care hospital of West Bengal.

AIMS-

To determine the clinico-epidemiological profile of *Acinetobacter* spp isolated from different ICU patients and to identify their antibiotic sensitivity pattern in a rural tertiary care hospital .

MATERIALS AND METHODS-

This is a cross sectional study which was performed from August 2023 to July 2024 at the Department of Microbiology of Tamralipto Government Medical College and Hospital, Tamluk, West Bengal. The study included 1911 samples received from patients admitted in the intensive care units of various department of our hospital including medicine, surgery, obstetrics and gynecology and pediatric ICU.

The specimens included urine, blood ,bronchoalveolar lavage (BAL) fluid, endotracheal (ET) tube aspirate, pus, cerebro-spinal fluid (CSF) and other body fluids. The aseptically collected specimens were inoculated on MacConkey agar & Blood agar and incubated aerobically at 37°C for 24-48 hrs. Presumptive identification was done on the basis of colony characteristics and Gram staining, followed by confirmation with standard biochemical tests such as catalase test, oxidase test, nitrate reduction test, oxidative/fermentative test.

Antibiotic sensitivity testing was performed by KirbyBauer disk-diffusion method on Muller Hinton Agar according to CLSI (Clinical Laboratory Standard Institute) guidelines 2023.

RESULTS-

Out of total 1911 clinical samples received from various departmental intensive care units, 1160 turned out to be culture positive and out of those culture positives, *Acinetobacter* sp was detected from 54 samples (4.66%). Maximum number were detected from pus samples (35.19%) followed by blood (22.22%), urine (18.52%), sputum (9.26%), ET tube (7.41%), BAL fluid (3.70%), CSF (1.85%) and ascitic fluid (1.85%). Table 1 shows the distribution of *Acinetobacter* sp among various clinical samples.

Maximum number of *Acinetobacter* sp was detected from Medicine ICU (51.85%) followed by paediatric ICU (20.37%), Surgery ICU (18.52%) and gynaecology ICU (9.26%). The department wise distribution of *Acinetobacter* sp has been shown in Table 2.

Figure 1 shows that *Acinetobacter* infection was observed more among male patients (70.37%) than female patients (29.36%).

In the age group distribution shown in Figure 2 it has been observed that the elderly age group (>60 years) was the most affected by *Acinetobacter* sp infection.

In Table 3 showing antibiotic susceptibility pattern of *Acinetobacter* strains, >80% resistance was observed towards several classes of antibiotics such as Aminoglycosides, Cephalosporins, Fluoroquinolones, Tetracyclines while maximum sensitivity was seen towards Colistin.

Table 1: Distribution of *Acinetobacter* sp. among various clinical samples

Clinical samples	No of <i>Acinetobacter</i> sp detected n=54	Percentage
Blood	12	22.22%
Pus	19	35.19%
Urine	10	18.52%
Sputum	5	9.26%
CSF	1	1.85%
Ascitic fluid	1	1.85%
ET tube	4	7.41%
BAL fluid	2	3.70%

Table 2: Departmental ICU wise distribution of cases

Department wise ICU	No of <i>Acinetobacter</i> sp detected n=54	percentage
Medicine ICU	28	51.85%
Gynaecology & Obstetrics ICU	5	9.26%
Paediatric ICU	11	20.37%
Surgical ICU	10	18.52%




Figure 1: Gender wise distribution of cases




Figure 2: Age group wise distribution of cases

Table 3: AST pattern among Acinetobacter isolates

Antibiotics	Sensitive	Intermediate	Resistant
Amikacin	5 (9.26%)	2 (3.70%)	47 (87.04%)
Gentamicin	6 (11.11%)	3 (5.56%)	45 (83.33%)
Ceftriaxone	6 (11.11%)	2 (3.70%)	46 (85.19%)
Cefotaxime	7 (12.96%)	2 (3.70%)	45 (83.33%)
Ciprofloxacin	6 (11.11%)	3 (5.56%)	45 (83.33%)
Tetracycline	8 (14.81%)	2 (3.70%)	44 (81.48%)
Cefoperazone-Sulbactam	34 (62.96%)	3 (5.56%)	17 (31.48%)
Imipenem	36 (66.67%)	4 (7.41%)	14 (25.93%)
Cotrimoxazole	8 (14.81%)	2 (3.70%)	44 (81.48%)
Colistin	42 (77.78%)	1 (1.85%)	11 (20.37%)

DISCUSSION-



Acinetobacter sp has emerged as an opportunistic nosocomial pathogen which is often multidrug resistant (MDR) and is responsible for life threatening infections among hospitalized patients, particularly in ICUs.^{3,9,10,11} Its ability to survive on inanimate objects, particularly hospital surfaces and equipments, for prolonged periods of time makes it extremely difficult to control the nosocomial spread.^{3,12}

In our study *Acinetobacter sp* accounted for 4.66% of culture positive samples which is a similar finding to few previous studies.^{1,13,14} Other studies by Dash M *et al*¹⁵ and Gupta N *et al*¹⁶ also show close findings to our study with *Acinetobacter sp* accounting for 3% and 3.36% of culture positive samples respectively. On the other hand studies by Oberoi *et al*¹⁷ and Lahiri KK *et al*¹⁸ have shown higher incidence of *Acinetobacter* infection.

In the present study maximum number of *Acinetobacter sp* was isolated from pus (35.19%) followed by blood (22.22%) urine (18.52%) and respiratory samples, similar findings have been shown in studies by Islahi Sana *et al*, Dash M *et al*¹⁵ and Mishra *et al*¹⁹. But studies by Sinha *et al*¹³ and Padersen *et al*²⁰ show maximum number of *Acinetobacter sp* were isolated from urine while in the study by Kaur TA *et al*³ maximum number of *Acinetobacter sp* was isolated from respiratory samples.

The departmental ICU wise distribution of *Acinetobacter sp* in our study has shown maximum number of *Acinetobacter sp* was detected from Medicine ICU (51.85%) followed by paediatric ICU (20.37%), Surgery ICU (18.52%) and gynaecology ICU (9.26%).

Similar to the study by Islahi Sana *et al*, *Acinetobacter* infection in the present study was observed more among male patients (70.37%) than female patients (29.63%). Patients above 40 years age were affected the highest in our study which is similar to the finding in the study by Gupta N *et al*.¹⁶ The reason might be due to reduced immunity as well as associated co-morbidities and chronic diseases in this age group.¹⁶

Susceptibility pattern of *Acinetobacter* strains to various antibiotics shows quite high prevalence of multi drug resistance. >80% resistance was observed towards several classes of antibiotics such as Aminoglycosides, Cephalosporins, Fluoroquinolones and Tetracyclines while maximum sensitivity (77.78%) was seen towards Colistin. 31.48% resistance was seen towards Cefoperazone-Sulbactam and 25.93% resistance towards Imipenem. Several previous studies^{1,3,15,16} have also shown multi drug resistance (MDR) of *Acinetobacter sp*. The above observation of broad spectrum antimicrobial resistance makes the management of *Acinetobacter sp* infections challenging and thus, shows the importance of taking serious measures to restrict the use of antimicrobials for only situations where they are actually needed and with proper dosing for a proper duration of time.³

CONCLUSION-

The MDR nature of *Acinetobacter sp* poses a severe threat to immunocompromised patients and ICU inhabitants. This highlights the importance of strengthening surveillance and monitoring at health-care setups to identify colonizers and reservoirs of this microorganism and plan effective infection control strategies. This should be combined with antibiotic stewardship program for developing new treatment options for these hospital-based MDR *Acinetobacter sp*.

Conflict of interest –NIL

Source of funding – None declared

REFERENCES

1. Islahi Sana *et al*. "Prevalence and resistance pattern of *Acinetobacter* species in hospitalized patients in a tertiary care centre." *Journal of Evolution of Medical and Dental Sciences*, vol. 3, no. 17, 28 Apr. 2014, pp. 4629
2. Dimple Raina *et al*. "Speciation and antibiotic resistance pattern of *Acinetobacter* species in a tertiary care hospital in Uttarakhand." *International Journal of Medical Research and Health Sciences* 5 (2016): 172-179.
3. Kaur TA, Putatunda CH, Oberoi AR, Vyas AS, Kumar GA. Prevalence and drug resistance in *Acinetobacter sp*. isolated from intensive care unit patients in Punjab, India. *Asian J Pharm Clin Res*. 2018 Jul;11(14):88-93.
4. Uwingabiye J, Frikh M, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, Dahraoui S, Belyamani L, Bait A, Haimeur C, Louzi L, Ibrahimi A, Elouennass M. *Acinetobacter* infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units. *Pan Afr Med J*. 2016 Apr 15;23:191. doi: 10.11604/pamj.2016.23.191.7915. PMID: 27347280; PMCID: PMC4907753.
5. García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Pérez-Paredes C, Barrero-Almodóvar AE, Gili-Miner M. Risk Factors for *Acinetobacter baumannii* Nosocomial Bacteremia in Critically Ill Patients: a Cohort Study. *Clin Infect Dis*. 2001;33(7):939–46.



6. Shareek PS, Sureshkumar D, Ramgopalakrishnan ,Ramasubramanian V, Ghafur KA, Thirunarayanan MA. Antibiotic Sensitivity Pattern of Blood Isolates of Acinetobacter Species in a Tertiary Care Hospital: A Retrospective Analysis. *Am J Infect Dis.* 2012;8(1):65–69
7. Somily AM, Absar MM, Arshad MZ, Al Aska AI, Shakoor ZA, Fatani AJ, Siddiqui YM, Murray TS. Antimicrobial susceptibility patterns of multidrug resistant *Pseudomonas aeruginosa* and *Acinetobacterbaumannii* against carbapenems, colistin, and tigecycline. *Saudi Med J.* 2012;33(7):750–755.
8. Baral S, Pokharel A, Subramanya SH, Nayak N. Clinico-epidemiological profile of *Acinetobacter* and *Pseudomonas* infections, and their antibiotic-resistant pattern in a tertiary care center, Western Nepal. *Nepal Journal of Epidemiology.* 2019 Dec;9(4):804.
9. Tomasz A. Multiple antibiotic resistant pathogenic bacteria. *N Engl J Med* 1994; 330:1247-51
10. Corbella X, Montero A, Pujol M. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant *Acinetobacterbaumannii*. *J ClinMicrobiol* 2000; 38: 4086-95.
11. Bergogne-Berezin E, Towner KJ. *Acinetobacter* species a nosocomial pathogen. Microbiological, clinical and epidemiological features. *ClinMicrobiol Rev* 1999; 9:148-65.
12. Sannathimmappa MB, Nambiar V, Aravindakshan R. Antibiotic resistance pattern of *Acinetobacterbaumannii* strains: a retrospective study from Oman. *Saudi Journal of Medicine & Medical Sciences.* 2021 Sep 1;9(3):254-60.
13. Sinha N, Agarwal J, Srivastava S, Singh M. Analysis of carbapenem-resistant *Acinetobacter* from a tertiary care setting in North India. *Indian J of Med Microbiol* 2013; 31 (1):60-3.
14. Lone R, Shah A, Kadri SM, Lone S, Shah F. Nosocomial multi-drug resistant *Acinetobacter* infections- clinical findings, risk factors and demographic characteristics. *Bangladesh J Med Microbiol.* 2009;03:34–8
15. Dash M, Padhi S, Pattnaik S, Mohanty I, Misra P. Frequency, risk factors, and antibiogram of *Acinetobacter* species isolated from various clinical samples in a tertiary care hospital in Odisha, India. *Avicenna journal of Medicine.* 2013 Oct;3(04):97-102.
16. Gupta N, Gandham N, Jadhav S, Mishra RN. Isolation and identification of *Acinetobacter* species with special reference to antibiotic resistance. *Journal of natural science, biology, and medicine.* 2015 Jan;6(1):159.
17. Oberoi A, Aggarwal A, Lal M. A decade of an underestimated nosocomial pathogen *Acinetobacter* in a tertiary care hospital in Punjab. *JK Sci* 2009; 11:24-6
18. Lahiri KK, Mani NS, Purai SS. *Acinetobacter* spp as nosocomial pathogen: Clinical significance and antimicrobial sensitivity. *Med J Armed Forces India.* 2004;60:7–10. doi: 10.1016/S0377-1237(04)80148-5.
19. Mishra B, Bhujwala RA, Shriniwas. Non fermenters in human infections. *Ind J Med Res* 1986; 83: 561-6.
20. Pedersen MM, Marso E, Pickett MJ. Non fermentative bacilli associated with man III pathogenicity and antibiotic susceptibility. *Am J ClinPathol* 1970; 54:178.